2021
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Tindana P, de Haan F, Mokuolu O, Guissou R, Bolarinwa O, Ouedraogo J, Tou F, Boon W, Moors E, Dondorp A, Dhorda M, Amaratunga C, Cheah P. Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol. Wellcome Open Research 2021, 6: 75. PMID: 34458588, PMCID: PMC8378406, DOI: 10.12688/wellcomeopenres.16065.1.Peer-Reviewed Original ResearchArtemisinin combination therapyCombination therapyQualitative research methodsViews of stakeholdersDepth interviewsPosition issuesMarket-related issuesCommunity membersNational Malaria Control ProgrammeGlobal malaria deathsArtemisinin combination treatmentSoutheast AsiaGroup discussionsNational regulatory authoritiesMalaria control programmesResearch methodsAfricaACT resistanceMalaria deathsMalaria treatmentStudy protocolMalaria prevalenceAntimalarial medicinesCombination treatmentStakeholders
2016
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valéa I, Sorgho H, Owusu-Dabo E, Ouédraogo J, Guiguemdé T, Tinto H. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE 2016, 11: e0151565. PMID: 27031231, PMCID: PMC4816516, DOI: 10.1371/journal.pone.0151565.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsBurkina FasoChildDrug CombinationsEthanolaminesFemaleFluorenesGene FrequencyGenotypeHost-Parasite InteractionsHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMultivariate AnalysisParasitemiaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsTreatment OutcomeConceptsPfmdr1 allelesTreatment failureArtemether-lumefantrine therapyPfcrt K76TSingle nucleotide polymorphismsRestriction fragment length polymorphism methodFragment length polymorphism methodPotential beneficial effectsLength polymorphism methodArtesunate-AmodiaquineRecurrent parasitaemiaTreatment regimenACT resistanceCombination therapyK76TPfmdr1 geneClinical trialsTreatment outcomesMultivariate analysisDay 0PfcrtMalaria controlBlood spotsBeneficial effectsPolymorphism method